CSF1R and cancer: In another trial (NCT02923739), Emactuzumab lowered TAMs by inhibiting CSF1R, improving anti-cancer immune responses and objective response rates up to 86% in diffuse-type tenosynovial giant cell tumors in early-phase trials.